Modality
Nanobody
MOA
CDK4/6i
Target
IL-23
Pathway
Ferroptosis
Wilms
Development Pipeline
Preclinical
~Nov 2023
→ ~Feb 2025
Phase 1
May 2025
→ Aug 2029
Phase 1Current
NCT04468016
334 pts·Wilms
2025-05→2029-08·Completed
334 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-08-103.4y awayInterim· Wilms
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1
Complet…
Catalysts
Interim
2029-08-10 · 3.4y away
Wilms
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04468016 | Phase 1 | Wilms | Completed | 334 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 |